Navigation Links
Cell Therapeutics Reports Second Quarter 2013 Financial Results
Date:7/31/2013

ent of its clinical trials; that CTI cannot predict or guarantee the outcome of preclinical and clinical studies; that CTI may not obtain reimbursement for PIXUVRI in certain markets in the E.U. as planned or at all; that the conditional marketing authorization for PIXUVRI may not be renewed or may be subject to additional conditions; that the second Phase 3 clinical trial of pacritinib will not occur as planned or at all; that CTI may not obtain favorable determinations by other regulatory, patent and administrative governmental authorities; that CTI may experience delays in the commencement of preclinical and clinical studies; risks related to the costs of developing, producing and selling PIXUVRI, pacritinib, and CTI's other product candidates; and other risks, including, without limitation, competitive factors, technological developments, costs of developing, producing and selling PIXUVRI, that CTI's operating expenses continue to exceed its net revenues, that CTI may not be able to sustain its current cost controls or further reduce its operating expenses, that CTI's average net operating burn rate may increase, that CTI will continue to need to raise capital to fund its operating expenses, but may not be able to raise sufficient amounts to fund its continued operation, as well as other risks listed or described from time to time in CTI's most recent filings with the Securities and Exchange Commission on Forms 10-K, 10-Q and 8-K.  Except as required by law, CTI does not intend to update any of the statements in this press release upon further developments.

PIXUVRI is a registered trademark of Cell Therapeutics, Inc.

Contacts:Monique Greer
+1 206.272.4343
mgreer@ctiseattle.com

Ed Bell
+1 206.282.7100
ebell@ctiseattle.com

In EuropeCTI Life Sciences Limited, Milan Branch
Laura Villa
+39 02 89659706

SOURCE Cell Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Cell Therapeutics, Inc. (CTI) to Report First Quarter Financial Results on April 20
2. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing in Chelsea Therapeutics International, Ltd. to Contact the Firm
3. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
4. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
5. Zacks Industry Outlook Highlights: Eli Lilly, Forest Labs, ViroPharma, Novartis and United Therapeutics
6. Oxford BioTherapeutics Appoints Senior Industry Leader to Head its New Clinical Development Operations in Basel, Switzerland
7. Nektar Therapeutics Reports Financial Results for the First Quarter of 2012
8. Cara Therapeutics Licenses Novel Kappa Opioid Agonist, CR845, to Chong Kun Dang Pharmaceutical Corporation For South Korean Market
9. Frost & Sullivan: High Uptake of New Drug Therapies and Aging Population Expansion Keep the U.S. Retinal Therapeutics Market Buoyant
10. Zenobia Therapeutics, Inc. And BioBlocks, Inc. Announce Sale Of A Joint Fragment Library Ideal For Screening By All Popular Methods
11. New Forecast Shows Global Protein Therapeutics Market to Reach $143.4 Billion by 2015
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014 The Cadence Fitness ... Fitness Center by the Medical Fitness Association, a non-profit ... achieve their full potential. The Cadence Fitness & Health ... western suburbs and second in the Chicagoland area. ...
(Date:1/15/2014)... Jan. 15, 2014  Valeant Pharmaceuticals International, Inc. (NYSE: ... applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act ... tender offer by its indirect wholly-owned subsidiary, Sapphire Subsidiary ... common stock of Solta Medical, Inc. (NASDAQ: ...
(Date:1/15/2014)... 2014  A novel wearable injector slightly larger than an Oreo ... to self-inject prescription drugs in the large doses required to ... autoimmune deficiencies, and genetic disorders.  An emerging ... 2018, according to analysts.   Many of these drugs will require ...
Breaking Medicine Technology:Cadence Fitness & Health Center Certified as Medical Fitness Facility 2Cadence Fitness & Health Center Certified as Medical Fitness Facility 3Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2
... Chiltern International Limited (Chiltern), a global contract research organization ... of their successful collaboration in Drug Phototoxicity. ... using a validated and regulatory accepted in vivo ... phototoxicity. The history of this collaboration can be traced ...
... 2011 Glenveigh Medical, LLC and Monica Healthcare Limited ... the United States as well as US territories and ... system. The system recently received FDA regulatory clearance for ... name Beacon by Monica™ , the wireless fetal ...
Cached Medicine Technology:Chiltern - Spectratox Drug Photoxicity Collaboration Celebrates 25 Years 2Chiltern - Spectratox Drug Photoxicity Collaboration Celebrates 25 Years 3Glenveigh Medical and Monica Healthcare Announce Distribution Agreement for Groundbreaking FDA Cleared Wireless Fetal Monitoring System 2
(Date:4/17/2014)... potential to ward off depression among retirees, particularly among ... in The Journals of Gerontology, Series B: ... article " Internet Use and Depression Among Retired Older ... the authors report that Internet use reduced the probability ... study sample. , Late-life depression affects between 5 ...
(Date:4/17/2014)... Population Council scientists and their partners have found that ... prevent the transmission of multiple sexually transmitted infections (STIs) ... herpes simplex virus 2 (HSV-2), and human papillomavirus (HPV). ... the gel is effective against multiple strains of HIV, ... against all three viruses of at least eight hours ...
(Date:4/17/2014)... April 17, 2014 Meaningful long-term survival ... cancer of the abdomen when treated with cytoreductive ... to a first-of-its-size analysis by physicians at Wake ... has the largest reported, single-center experience with cytoreductive ... Levine, M.D., and analysis of 20 years, worth ...
(Date:4/17/2014)... is less than 40 years away from a food ... governments, according to a top scientist at the U.S. ... human history, food production will be limited on a ... energy," said Dr. Fred Davies, senior science advisor for ... become as politically destabilizing by 2050 as energy issues ...
(Date:4/17/2014)... 94 per cent of Canadians surveyed said they would ... a specific number of genetic conditions, only 80 per ... screening that would sequence their newborns, genomes.,Most newborns in ... first day or two of life in which a ... and tested for about five to 54 conditions, depending ...
Breaking Medicine News(10 mins):Health News:Internet use may cut retirees' depression 2Health News:Animal study provides first evidence that gel can prevent multiple virus transmission in vagina/rectum 2Health News:20 years of data shows treatment technique improvement for advanced abdominal cancer 2Health News:Food shortages could be most critical world issue by mid-century 2Health News:Researcher looks at public perceptions around newborn testing 2Health News:Researcher looks at public perceptions around newborn testing 3
... Andhra women have financed the bypass surgery of a fisherwoman ... to their efforts, B. Hemavati, 35, wife of a fisherman ... operation at the Tirupati-based Sri Venkateswara Institute of Medical Sciences ... Godavari district, was diagnosed with a heart ailment that doctors ...
... computerized tomography (CBCT) is increasingly becoming a potent tool ... ,J. Martin Palomo and Mark Hans from the department ... of Dental Medicine and C.H. Kau and S. Richmond ... at the University of Wales' College of Medicine have ...
... identified by the Oregon National Primate Research Center at ... to control stem cells becoming other brain cells.// New ... and brain injury as a result of continued research. ... early stages before birth, which become glial cells in ...
... to the role religion plays in a patient's life positively ... for female medicos and no, for male medicos.// ... of the Southern Medical Journal, patients want their physicians to ... to discuss religious issues with them, especially if they are ...
... scientist at Schepens Eye Research Institute (SERI) found that ... television watching more enjoyable to the visually impaired. // ... develop an electronic device to help millions suffering eye ... include those suffering from macular degeneration, diabetic retinopathy and ...
... Zealand government plans to contain it. ,They are preparing ... It will be in multiple waves and will extend up to ... does not have facilities to // tackle such situations (pandemic). ... acute disasters. ,But in this case people are not ...
Cached Medicine News:Health News:Poor Andhra Women Enable Bypass Surgery Paying 50 Paise Each 2Health News:New Computerized Imaging Systems Help In Better Dental Treatment Planning 2Health News:Religious sensitivity of medicos gender-dependent 2Health News:Visually impaired prefer specially enhanced TV 2Health News:Visually impaired prefer specially enhanced TV 3
Excellent multi purpose agarose Nuclease-free, Gel point (1.5%): 36 1.5 C, EEO: 0.05-0.13 Gel strength (1%): > 1200 g/cm 2 ....
... NuSieve 3:1 Agarose is a molecular biology grade, ... for fine resolution of small DNA, RNA, and ... enhance the speed of gel processing and blotting. ... resolution of DNA fragments up to 1,000 bp, ...
... standard gelling temperature, high gel strength agarose ... bp. This Genetic Technology Grade™ (GTG) agarose ... DNA recovered from SeaKem GTG Agarose gels ... GTG Agarose is extensively performance tested to ...
... gel strength, high electrophoretic mobility, and ... is the superior choice for CHEF ... easy to handle at concentrations as ... run times. Low background staining also ...
Medicine Products: